Carla botting malaria vaccines oct 14 2013
•
1 like•1,286 views
This document summarizes a presentation on malaria vaccination goals and strategies. It outlines the global burden of malaria, with most cases and deaths occurring in sub-Saharan Africa. The original goal was to develop an 80% effective vaccine by 2025 that protects for 4 years. The updated goal is a world free of malaria partly due to affordable vaccines preventing disease/death from P. falciparum and P. vivax in all ages. Priority programs include the current RTS,S vaccine for children (ppRTS,S), evaluating RTS,S for elimination (eeRTS,S), and developing next generation RTS,S vaccines (eeRTS,S+) to contribute to elimination.
Report
Share
Report
Share
Download to read offline
Recommended
Recent advances in malaria
This document summarizes recent advances in malaria diagnosis, treatment, vaccines, and elimination efforts. It describes new diagnostic techniques like rapid diagnostic tests and molecular methods like PCR. It outlines recent treatment advances like new artemisinin-based combination therapies and injectable artesunate for severe malaria. It discusses the RTS,S malaria vaccine and new highly effective vaccine candidates in clinical trials. It also summarizes global strategies and targets for malaria elimination by 2030 through efforts like the WHO Global Malaria Programme, genetic research with MalariaGEN, and novel approaches like gene drive modified mosquitoes to reduce disease transmission.
Katie Flanagan - Malaria vaccines current status and challenges
Vaccines are considered the most cost-effective means of control, prevention, elimination, eradication of infectious diseases: for this reason, a malaria vaccine would greatly assist in the drive to eradicate malaria from the world. Professor Flanagan presents in this slideset the current status and challenges of developing malaria vaccines.
To learn more, visit www.waidid.org!
Malaria vaccine presentation
The document discusses the RTS,S/AS01 malaria vaccine candidate. It provides details on the development of RTS,S from initial designs incorporating the circumsporozoite protein to clinical trials demonstrating safety and efficacy. Phase 3 trials in African children showed RTS,S/AS01 reduced clinical malaria by approximately 50% and severe malaria by approximately 50% over 12 months. While the vaccine provided benefit, it also caused some adverse side effects and deaths. Ongoing research continues to improve vaccine design and development for a highly effective malaria vaccine.
Current status of Malaria vaccine (Nov 2016)
This document summarizes information about the current status of malaria vaccines. It discusses the burden of malaria worldwide and in India. It describes the life cycle of Plasmodium parasites and the different types of malaria. The key targets for malaria vaccines including pre-erythrocytic, blood stage, and transmission blocking vaccines are outlined. The currently available RTS,S vaccine is described including results from phase 3 trials showing moderate efficacy that wanes over time. Challenges in developing effective malaria vaccines are discussed such as applying traditional vaccine approaches, limitations of animal models, and waning vaccine efficacy. New malaria vaccine projects in India including JAIVAC-1 and JAIVAC-2 are briefly introduced.
Malaria vaccine
Basic concepts of malaria vaccine
and various vaccines in pipeline along with recently approved vaccine.
vaccine development against malaria parasite
- Malaria is caused by Plasmodium parasites and is a major tropical disease, especially in Africa. The most lethal species is P. falciparum.
- There are three main types of malaria vaccines targeting different life stages of the parasite: pre-erythrocytic (liver stage), blood stage, and transmission blocking vaccines.
- The leading and most advanced vaccine candidate is RTS,S/AS02, which targets the pre-erythrocytic stage and has reached phase III clinical trials. It consists of the CSP antigen fused to the hepatitis B surface antigen. Phase II trials demonstrated approximately 30% efficacy.
Malarial vaccine
The document discusses malaria, which infects hundreds of millions annually and kills over 1 million people per year, mostly in Africa. It outlines the challenges in developing an effective malaria vaccine, including the parasite's ability to evade the immune system and lack of animal models for testing. Several past and current vaccine candidates are mentioned, including SPf66 (the first field trial vaccine), RTS,S (the most advanced candidate to date), and PfSPZ Vaccine (a whole parasite vaccine showing promise in recent trials). Overall, the document reviews the state of malaria vaccine research and the hurdles remaining in developing a highly effective vaccine.
Malaria vaccine 5 mins
The document discusses the need for a malaria vaccine. Malaria parasites routinely develop resistance to antimalarial drugs and mosquitoes develop resistance to insecticides used to control populations. Vaccines have successfully eradicated other diseases like smallpox and polio. The goal of a malaria vaccine would be to prevent disease and death by breaking the cycle of transmission between mosquitoes and humans. Potential targets for vaccines include different stages of the parasite's life cycle. Considerations in developing an effective vaccine include antigen accessibility, susceptibility to evolution, role in parasite function, ability to induce protection in models, and compatibility with other antigens. The world's most clinically advanced candidate is RTS,S, which has been in development since the 1980s led
Recommended
Recent advances in malaria
This document summarizes recent advances in malaria diagnosis, treatment, vaccines, and elimination efforts. It describes new diagnostic techniques like rapid diagnostic tests and molecular methods like PCR. It outlines recent treatment advances like new artemisinin-based combination therapies and injectable artesunate for severe malaria. It discusses the RTS,S malaria vaccine and new highly effective vaccine candidates in clinical trials. It also summarizes global strategies and targets for malaria elimination by 2030 through efforts like the WHO Global Malaria Programme, genetic research with MalariaGEN, and novel approaches like gene drive modified mosquitoes to reduce disease transmission.
Katie Flanagan - Malaria vaccines current status and challenges
Vaccines are considered the most cost-effective means of control, prevention, elimination, eradication of infectious diseases: for this reason, a malaria vaccine would greatly assist in the drive to eradicate malaria from the world. Professor Flanagan presents in this slideset the current status and challenges of developing malaria vaccines.
To learn more, visit www.waidid.org!
Malaria vaccine presentation
The document discusses the RTS,S/AS01 malaria vaccine candidate. It provides details on the development of RTS,S from initial designs incorporating the circumsporozoite protein to clinical trials demonstrating safety and efficacy. Phase 3 trials in African children showed RTS,S/AS01 reduced clinical malaria by approximately 50% and severe malaria by approximately 50% over 12 months. While the vaccine provided benefit, it also caused some adverse side effects and deaths. Ongoing research continues to improve vaccine design and development for a highly effective malaria vaccine.
Current status of Malaria vaccine (Nov 2016)
This document summarizes information about the current status of malaria vaccines. It discusses the burden of malaria worldwide and in India. It describes the life cycle of Plasmodium parasites and the different types of malaria. The key targets for malaria vaccines including pre-erythrocytic, blood stage, and transmission blocking vaccines are outlined. The currently available RTS,S vaccine is described including results from phase 3 trials showing moderate efficacy that wanes over time. Challenges in developing effective malaria vaccines are discussed such as applying traditional vaccine approaches, limitations of animal models, and waning vaccine efficacy. New malaria vaccine projects in India including JAIVAC-1 and JAIVAC-2 are briefly introduced.
Malaria vaccine
Basic concepts of malaria vaccine
and various vaccines in pipeline along with recently approved vaccine.
vaccine development against malaria parasite
- Malaria is caused by Plasmodium parasites and is a major tropical disease, especially in Africa. The most lethal species is P. falciparum.
- There are three main types of malaria vaccines targeting different life stages of the parasite: pre-erythrocytic (liver stage), blood stage, and transmission blocking vaccines.
- The leading and most advanced vaccine candidate is RTS,S/AS02, which targets the pre-erythrocytic stage and has reached phase III clinical trials. It consists of the CSP antigen fused to the hepatitis B surface antigen. Phase II trials demonstrated approximately 30% efficacy.
Malarial vaccine
The document discusses malaria, which infects hundreds of millions annually and kills over 1 million people per year, mostly in Africa. It outlines the challenges in developing an effective malaria vaccine, including the parasite's ability to evade the immune system and lack of animal models for testing. Several past and current vaccine candidates are mentioned, including SPf66 (the first field trial vaccine), RTS,S (the most advanced candidate to date), and PfSPZ Vaccine (a whole parasite vaccine showing promise in recent trials). Overall, the document reviews the state of malaria vaccine research and the hurdles remaining in developing a highly effective vaccine.
Malaria vaccine 5 mins
The document discusses the need for a malaria vaccine. Malaria parasites routinely develop resistance to antimalarial drugs and mosquitoes develop resistance to insecticides used to control populations. Vaccines have successfully eradicated other diseases like smallpox and polio. The goal of a malaria vaccine would be to prevent disease and death by breaking the cycle of transmission between mosquitoes and humans. Potential targets for vaccines include different stages of the parasite's life cycle. Considerations in developing an effective vaccine include antigen accessibility, susceptibility to evolution, role in parasite function, ability to induce protection in models, and compatibility with other antigens. The world's most clinically advanced candidate is RTS,S, which has been in development since the 1980s led
9 Malaria Vaccine (1)
MVI is working with ICGEB in India to develop a vaccine against Plasmodium vivax. This effort includes Bharat Biotech, which will manufacture the vaccine for preclinical and initial safety trials in adults. The vaccine aims to prevent infection, decrease infection intensity, and prevent malaria transmission.
Malaria vaccine
A malaria vaccine is a vaccine that is used to prevent malaria. The only approved vaccine as of 2015 is RTS,S, known by the trade name Mosquirix. It requires four injections and has a relatively low efficacy.
Malaria vaccine
This document summarizes information about malaria vaccines. It discusses how malaria is caused by Plasmodium parasites and transmitted by mosquitoes. Four species can infect humans. Current vaccines target different stages of the parasite's life cycle, including pre-erythrocytic, blood, and sexual stages. Challenges to vaccine development include the parasite's ability to evade the immune system through antigenic variation. Several candidate vaccines are discussed that target different stages, but none have achieved high levels of efficacy and durability.
Malaria vaccine
No commercially available malaria vaccine at the present time.
RTS,S/AS01 is the most advanced vaccine candidate against malaria.
Commonest infectious disease in the tropics
200 millions per year affected with malaria
3 millions per year die due to malaria
Presentation by adrian hill [university of oxford]
Malaria is a major global health problem, killing over 700,000 people annually. Developing an effective vaccine is challenging due to the parasite's complex life cycle and ability to evade the immune system. Current vaccine approaches include protein-adjuvant vaccines targeting specific stages, viral vectored vaccines to induce cellular immunity, and whole parasite vaccines. Significant progress has been made, but partial efficacy has required unprecedented immunogenicity. A multi-component vaccine targeting multiple stages may be needed for high efficacy.
Malaria vaccine
This document provides information about malaria vaccines. It discusses the context of malaria globally and the need for a vaccine. Several potential vaccine candidates target different stages of the malaria parasite's lifecycle, including sporozoites, infected hepatocytes, and erythrocytic stages. Developing an effective vaccine is challenging due to the parasite's diversity and complexity. The most promising current candidate is RTS,S, which provides some protection against malaria in clinical trials but is not fully effective.
Malaria Vaccine Development: A Step Towards Reality
Malaria, a protozoan parasitic disease caused by five species of Plasmodium i.e., P. vivax, P. falciparum, P. malariae, P. ovale and P. knowlesi in humans. Nearly half of the world’s population, an estimated 3.3 billion people in 97 countries and territories are at risk of malaria infection and 1.2 billon are at high risk (> 1 case of malaria per 1000 population each year) [1]. According to world malaria report 2014, 198 million cases of malaria occurred globally in 2013 (uncertainty range 124-283 million) and the disease led to 584,000 deaths
(uncertainty range 367,000-755,000) [1]. Among five species of Plasmodium, the most dangerous P. falciparum malaria remains the commonest cause of under-five mortality in several countries [2].
Antimalarial vaccines
The document discusses the need for a malaria vaccine and challenges in developing one. It provides details on various vaccine candidates and approaches, including pre-erythrocytic (preventing infection of liver), asexual blood stage (preventing growth in red blood cells), and sexual stage (blocking transmission) vaccines. Top candidates mentioned are RTS,S/AS02, which has undergone phase 3 trials, and SPf66, the first to undergo field testing. Developing an effective and durable malaria vaccine faces difficulties due to the parasite's complex life cycle and ability to evade the immune system.
Malaria
1) Malaria vaccines aim to prevent infection, decrease disease severity, and reduce transmission. However, developing an effective malaria vaccine is challenging due to the parasite's high mutation rate and ability to evade the immune system.
2) Most research focuses on P. falciparum since it causes the most mortality. Potential vaccine candidates target different stages of the parasite's life cycle and include antigens like CSP, AMA1, MSP1, and Pfs25.
3) SPf66 was the first malaria vaccine tested in humans but showed limited efficacy. RTS,S is the most advanced candidate vaccine and has demonstrated up to 50% efficacy in clinical trials. However, more research is still needed to develop
PATH Malaria Vaccine Initiative
MVI's mission is to accelerate malaria vaccine development and ensure availability in developing countries. Its goal is an 80% effective vaccine lasting 4+ years by 2025. Malaria infects 250 million people annually and kills 900,000, mostly children in Africa. Vaccine development faces challenges due to the parasite's complexity and limited commercial markets. MVI partners with organizations to systematically develop promising approaches through clinical trials. Its current strategy focuses on pre-erythrocytic, transmission-blocking, and P. vivax vaccines. With a phase 3 trial underway, MVI's public-private model brings malaria vaccines closer to reality.
HIV Vaccine
Over 60 million people have been infected with HIV since 1981, and 39.5 million people are currently living with HIV. There are still around 4.3 million new infections each year, and over 28 million people have died of AIDS-related illnesses since the start of the pandemic. Developing an effective HIV vaccine has proven extremely challenging due to the virus's ability to mutate and evade the immune system. While several vaccine candidates have reached clinical trials, none have yet provided reliable, long-term sterilizing immunity. Continued research efforts aim to develop a vaccine that can eliminate HIV infections and end the pandemic.
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
The document provides an overview of HIV/AIDS vaccine research and development efforts. It discusses the global impact of HIV/AIDS, the need for an effective vaccine, the various phases of vaccine development and testing, different vaccine candidates currently being tested including peptide epitopes, viral proteins, and viral vectors, as well as some of the large phase 2 and 3 clinical trials underway. It emphasizes that developing a safe and effective HIV vaccine will require a global collaborative effort.
HIV Vaccine Development Strategies
This document summarizes different strategies for developing an HIV vaccine, outlining the challenges and current state of different vaccine types. It discusses how vaccines could potentially prevent or treat HIV infection, and highlights the obstacles like HIV's ability to mutate and target immune cells. Different vaccine types currently in clinical trials are described, including peptides, DNA, live vectors, and recombinant proteins. The largest vaccine trial to date, AIDSVAX, is summarized as stimulating antibodies but not proving effective against HIV.
Dr iwalokun presentation_amls_lagosstate_2018
This presentation is about the relevance of vaccine as a public health tool against vaccine preventable diseases and the need to accelerate the development of vaccines against malaria and other diseases of global health importance in developing countries such as Nigeria.
From Discovery to Delivery: Benchwork to Global Health: Shiu-Lok Hu
Explores relationships and discrepancies between important research-based medical advancements and subsequent real world implementation. Advancements in the management and potential elimination of infectious diseases such as HIV and TB will be addressed, as related to development and implementation of effective diagnostics, vaccines, or treatments.
Rotavirus prevention and control
This document discusses rotavirus prevention and control. It begins with an introduction stating that rotavirus is the leading cause of severe diarrhea in children under 5 globally, resulting in over 500,000 child deaths annually. The majority of these deaths occur in low-income countries.
It then covers the epidemiology and disease burden, describing rotavirus as the top cause of death in children under 5 worldwide. Clinical presentation is discussed, outlining the typical timeline and symptoms of rotavirus infection.
Prevention and control methods are summarized as infection control practices and vaccination. Two oral rotavirus vaccines currently available are described and their efficacy and safety are discussed. WHO recommendations for rotavirus vaccination through national immunization
Prof. anzala hiv vaccine update
The document outlines research being conducted at KAVI-ICR on HIV vaccine development. It discusses current global progress including some vaccines that showed efficacy and others that did not. KAVI is conducting several phase 1 clinical trials of vaccine candidates alone or in prime-boost combinations. The goal is to advance candidates that elicit broadly neutralizing antibodies or durable cellular immune responses to control HIV infection. Challenges include HIV's variability, but replicating viral vectors and designing immunogens to target specific sites on HIV show promise.
Vaccine trials on aids
The document discusses the need for an AIDS vaccine, approaches to developing one, and challenges. It outlines several clinical trials that have been conducted, including tgAAC09 which found the vaccine was generally safe but weakly immunogenic. The MRKAd5 HIV-1 gag/pol/nef vaccine did not prevent HIV infection or reduce virus levels. The RV144 trial found the ALVAC/AIDSVAX regimen was safe and 31.2% effective at preventing HIV infection, representing progress for an HIV vaccine. Developing an effective AIDS vaccine remains difficult due to HIV's ability to evade the immune system.
Professor Cal MacLennan
Gonorrhea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae that can lead to serious health complications if left untreated. There is an urgent need for a gonorrhea vaccine due to increasing antibiotic resistance and the potential for the disease to become untreatable. However, vaccine development faces several difficulties as N. gonorrhoeae is highly variable, able to avoid the immune system, and past vaccine trials have shown no efficacy. Continued research is focused on identifying conserved antigens that could induce a protective immune response through vaccination.
Hiv Vaccines Overview
This document provides an overview of HIV vaccines, including definitions, estimates of herd immunity thresholds for different diseases, types of vaccines, strategies for preventive and therapeutic HIV vaccines, and summaries of clinical trials. It discusses DNA vaccines, viral vector vaccines, dendritic cell vaccines, therapeutic vaccine candidates, and the Canadian HIV Vaccines Initiative.
National Vector Borne Disease Control Program.pptx
WELL THIS IS ABOUT VECTOR BORNE DISEASE CONTROL PROGRAMME AND MALERIA IN DEPTH . OVERALL OVERVIEW OF NVBDCP HAS GIVEN AND THEN DETAILS ABOUT MALERIA ARE DISCUSSED AND ALL OTHER DISEASES IN PROGRAMME ARE ALSO COVERED.
4607658.ppt
Malaria is a mosquito-borne disease that is a major public health problem worldwide, especially in developing countries. It is a leading cause of death, particularly among young children and pregnant women in Africa. The majority of malaria cases occur in sub-Saharan Africa. Young children and pregnant women are the most vulnerable groups because their immunity is lowest. Controlling the disease requires preventing mosquito bites through measures like insecticide-treated bed nets as well as promptly diagnosing and treating infected individuals.
More Related Content
What's hot
9 Malaria Vaccine (1)
MVI is working with ICGEB in India to develop a vaccine against Plasmodium vivax. This effort includes Bharat Biotech, which will manufacture the vaccine for preclinical and initial safety trials in adults. The vaccine aims to prevent infection, decrease infection intensity, and prevent malaria transmission.
Malaria vaccine
A malaria vaccine is a vaccine that is used to prevent malaria. The only approved vaccine as of 2015 is RTS,S, known by the trade name Mosquirix. It requires four injections and has a relatively low efficacy.
Malaria vaccine
This document summarizes information about malaria vaccines. It discusses how malaria is caused by Plasmodium parasites and transmitted by mosquitoes. Four species can infect humans. Current vaccines target different stages of the parasite's life cycle, including pre-erythrocytic, blood, and sexual stages. Challenges to vaccine development include the parasite's ability to evade the immune system through antigenic variation. Several candidate vaccines are discussed that target different stages, but none have achieved high levels of efficacy and durability.
Malaria vaccine
No commercially available malaria vaccine at the present time.
RTS,S/AS01 is the most advanced vaccine candidate against malaria.
Commonest infectious disease in the tropics
200 millions per year affected with malaria
3 millions per year die due to malaria
Presentation by adrian hill [university of oxford]
Malaria is a major global health problem, killing over 700,000 people annually. Developing an effective vaccine is challenging due to the parasite's complex life cycle and ability to evade the immune system. Current vaccine approaches include protein-adjuvant vaccines targeting specific stages, viral vectored vaccines to induce cellular immunity, and whole parasite vaccines. Significant progress has been made, but partial efficacy has required unprecedented immunogenicity. A multi-component vaccine targeting multiple stages may be needed for high efficacy.
Malaria vaccine
This document provides information about malaria vaccines. It discusses the context of malaria globally and the need for a vaccine. Several potential vaccine candidates target different stages of the malaria parasite's lifecycle, including sporozoites, infected hepatocytes, and erythrocytic stages. Developing an effective vaccine is challenging due to the parasite's diversity and complexity. The most promising current candidate is RTS,S, which provides some protection against malaria in clinical trials but is not fully effective.
Malaria Vaccine Development: A Step Towards Reality
Malaria, a protozoan parasitic disease caused by five species of Plasmodium i.e., P. vivax, P. falciparum, P. malariae, P. ovale and P. knowlesi in humans. Nearly half of the world’s population, an estimated 3.3 billion people in 97 countries and territories are at risk of malaria infection and 1.2 billon are at high risk (> 1 case of malaria per 1000 population each year) [1]. According to world malaria report 2014, 198 million cases of malaria occurred globally in 2013 (uncertainty range 124-283 million) and the disease led to 584,000 deaths
(uncertainty range 367,000-755,000) [1]. Among five species of Plasmodium, the most dangerous P. falciparum malaria remains the commonest cause of under-five mortality in several countries [2].
Antimalarial vaccines
The document discusses the need for a malaria vaccine and challenges in developing one. It provides details on various vaccine candidates and approaches, including pre-erythrocytic (preventing infection of liver), asexual blood stage (preventing growth in red blood cells), and sexual stage (blocking transmission) vaccines. Top candidates mentioned are RTS,S/AS02, which has undergone phase 3 trials, and SPf66, the first to undergo field testing. Developing an effective and durable malaria vaccine faces difficulties due to the parasite's complex life cycle and ability to evade the immune system.
Malaria
1) Malaria vaccines aim to prevent infection, decrease disease severity, and reduce transmission. However, developing an effective malaria vaccine is challenging due to the parasite's high mutation rate and ability to evade the immune system.
2) Most research focuses on P. falciparum since it causes the most mortality. Potential vaccine candidates target different stages of the parasite's life cycle and include antigens like CSP, AMA1, MSP1, and Pfs25.
3) SPf66 was the first malaria vaccine tested in humans but showed limited efficacy. RTS,S is the most advanced candidate vaccine and has demonstrated up to 50% efficacy in clinical trials. However, more research is still needed to develop
PATH Malaria Vaccine Initiative
MVI's mission is to accelerate malaria vaccine development and ensure availability in developing countries. Its goal is an 80% effective vaccine lasting 4+ years by 2025. Malaria infects 250 million people annually and kills 900,000, mostly children in Africa. Vaccine development faces challenges due to the parasite's complexity and limited commercial markets. MVI partners with organizations to systematically develop promising approaches through clinical trials. Its current strategy focuses on pre-erythrocytic, transmission-blocking, and P. vivax vaccines. With a phase 3 trial underway, MVI's public-private model brings malaria vaccines closer to reality.
HIV Vaccine
Over 60 million people have been infected with HIV since 1981, and 39.5 million people are currently living with HIV. There are still around 4.3 million new infections each year, and over 28 million people have died of AIDS-related illnesses since the start of the pandemic. Developing an effective HIV vaccine has proven extremely challenging due to the virus's ability to mutate and evade the immune system. While several vaccine candidates have reached clinical trials, none have yet provided reliable, long-term sterilizing immunity. Continued research efforts aim to develop a vaccine that can eliminate HIV infections and end the pandemic.
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
The document provides an overview of HIV/AIDS vaccine research and development efforts. It discusses the global impact of HIV/AIDS, the need for an effective vaccine, the various phases of vaccine development and testing, different vaccine candidates currently being tested including peptide epitopes, viral proteins, and viral vectors, as well as some of the large phase 2 and 3 clinical trials underway. It emphasizes that developing a safe and effective HIV vaccine will require a global collaborative effort.
HIV Vaccine Development Strategies
This document summarizes different strategies for developing an HIV vaccine, outlining the challenges and current state of different vaccine types. It discusses how vaccines could potentially prevent or treat HIV infection, and highlights the obstacles like HIV's ability to mutate and target immune cells. Different vaccine types currently in clinical trials are described, including peptides, DNA, live vectors, and recombinant proteins. The largest vaccine trial to date, AIDSVAX, is summarized as stimulating antibodies but not proving effective against HIV.
Dr iwalokun presentation_amls_lagosstate_2018
This presentation is about the relevance of vaccine as a public health tool against vaccine preventable diseases and the need to accelerate the development of vaccines against malaria and other diseases of global health importance in developing countries such as Nigeria.
From Discovery to Delivery: Benchwork to Global Health: Shiu-Lok Hu
Explores relationships and discrepancies between important research-based medical advancements and subsequent real world implementation. Advancements in the management and potential elimination of infectious diseases such as HIV and TB will be addressed, as related to development and implementation of effective diagnostics, vaccines, or treatments.
Rotavirus prevention and control
This document discusses rotavirus prevention and control. It begins with an introduction stating that rotavirus is the leading cause of severe diarrhea in children under 5 globally, resulting in over 500,000 child deaths annually. The majority of these deaths occur in low-income countries.
It then covers the epidemiology and disease burden, describing rotavirus as the top cause of death in children under 5 worldwide. Clinical presentation is discussed, outlining the typical timeline and symptoms of rotavirus infection.
Prevention and control methods are summarized as infection control practices and vaccination. Two oral rotavirus vaccines currently available are described and their efficacy and safety are discussed. WHO recommendations for rotavirus vaccination through national immunization
Prof. anzala hiv vaccine update
The document outlines research being conducted at KAVI-ICR on HIV vaccine development. It discusses current global progress including some vaccines that showed efficacy and others that did not. KAVI is conducting several phase 1 clinical trials of vaccine candidates alone or in prime-boost combinations. The goal is to advance candidates that elicit broadly neutralizing antibodies or durable cellular immune responses to control HIV infection. Challenges include HIV's variability, but replicating viral vectors and designing immunogens to target specific sites on HIV show promise.
Vaccine trials on aids
The document discusses the need for an AIDS vaccine, approaches to developing one, and challenges. It outlines several clinical trials that have been conducted, including tgAAC09 which found the vaccine was generally safe but weakly immunogenic. The MRKAd5 HIV-1 gag/pol/nef vaccine did not prevent HIV infection or reduce virus levels. The RV144 trial found the ALVAC/AIDSVAX regimen was safe and 31.2% effective at preventing HIV infection, representing progress for an HIV vaccine. Developing an effective AIDS vaccine remains difficult due to HIV's ability to evade the immune system.
Professor Cal MacLennan
Gonorrhea is a sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae that can lead to serious health complications if left untreated. There is an urgent need for a gonorrhea vaccine due to increasing antibiotic resistance and the potential for the disease to become untreatable. However, vaccine development faces several difficulties as N. gonorrhoeae is highly variable, able to avoid the immune system, and past vaccine trials have shown no efficacy. Continued research is focused on identifying conserved antigens that could induce a protective immune response through vaccination.
Hiv Vaccines Overview
This document provides an overview of HIV vaccines, including definitions, estimates of herd immunity thresholds for different diseases, types of vaccines, strategies for preventive and therapeutic HIV vaccines, and summaries of clinical trials. It discusses DNA vaccines, viral vector vaccines, dendritic cell vaccines, therapeutic vaccine candidates, and the Canadian HIV Vaccines Initiative.
What's hot (20)
Presentation by adrian hill [university of oxford]
Presentation by adrian hill [university of oxford]
Malaria Vaccine Development: A Step Towards Reality
Malaria Vaccine Development: A Step Towards Reality
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
HIV Vaccine Research and HIV drugs in the pipeline HIV Vaccine Research and...
From Discovery to Delivery: Benchwork to Global Health: Shiu-Lok Hu
From Discovery to Delivery: Benchwork to Global Health: Shiu-Lok Hu
Similar to Carla botting malaria vaccines oct 14 2013
National Vector Borne Disease Control Program.pptx
WELL THIS IS ABOUT VECTOR BORNE DISEASE CONTROL PROGRAMME AND MALERIA IN DEPTH . OVERALL OVERVIEW OF NVBDCP HAS GIVEN AND THEN DETAILS ABOUT MALERIA ARE DISCUSSED AND ALL OTHER DISEASES IN PROGRAMME ARE ALSO COVERED.
4607658.ppt
Malaria is a mosquito-borne disease that is a major public health problem worldwide, especially in developing countries. It is a leading cause of death, particularly among young children and pregnant women in Africa. The majority of malaria cases occur in sub-Saharan Africa. Young children and pregnant women are the most vulnerable groups because their immunity is lowest. Controlling the disease requires preventing mosquito bites through measures like insecticide-treated bed nets as well as promptly diagnosing and treating infected individuals.
malaria write up 2b
Malaria is a life-threatening disease caused by Plasmodium parasites transmitted via mosquito bites. P. falciparum is the deadliest species. In 2010, malaria killed approximately 600,000 people, mostly young children and pregnant women in Africa. While control efforts have reduced malaria significantly outside of Africa, it remains a major public health challenge, exacerbated by emerging drug resistance and the overlap of malaria with poverty. Accurate diagnosis via microscopy of blood smears remains essential for effective treatment and control of this widespread and complex disease.
Future generation vaccines
The document summarizes future generation vaccines and their development. It discusses the need for vaccines against HIV, tuberculosis, malaria, dengue, and meningococcal diseases. For each disease, it outlines the disease burden, current vaccine development efforts including clinical trials, and the roles of organizations like WHO and PATH in accelerating vaccine development. The largest and most advanced vaccine clinical trials mentioned are for RTS,S malaria vaccine and Dengvaxia dengue vaccine.
Multidrug Resistant Malaria- Vani Vannappagari MBBS PhD
Plasmodium falciparum malaria poses a serious global health threat, with approximately 250 million cases and 1 million deaths annually. Drug resistance has developed to former first-line treatments such as chloroquine and sulfadoxine-pyrimethamine. Prompt diagnosis and treatment with artemisinin-based combination therapies can reduce the spread of resistance. Vaccine development remains challenging due to the parasite's ability to evade the immune system.
Multidrug Resistance malaria vani vannappagari mbbs ph d
Plasmodium falciparum malaria poses a serious global health threat, with approximately 250 million cases and 1 million deaths annually. Drug resistance has developed to former first-line treatments such as chloroquine and sulfadoxine-pyrimethamine. Prompt diagnosis and treatment with artemisinin-based combination therapies can reduce the spread of resistance. A malaria vaccine is still in development but one candidate, RTS,S, has shown promise in clinical trials in reducing malaria cases and severity.
polio endgame strategy and ipv introduction
This document discusses polio eradication efforts globally and in India. It provides background on the polio virus and disease. The key points are:
- The Global Polio Eradication Initiative was launched in 1988 and has reduced polio cases by over 99%, with only 3 endemic countries remaining.
- India introduced its Pulse Polio Immunization program in 1995 and was removed from the list of endemic countries in 2012 after its last case in 2011.
- The polio endgame strategy aims to stop all wild poliovirus transmission by 2014, introduce at least one dose of IPV, and eventually withdraw OPV, completing eradication by 2018.
- Surveillance of acute fl
Community acquired pneumonia (cap) in children
This document discusses community-acquired pneumonia (CAP) in children. It defines CAP and provides epidemiological data, noting that CAP affects over 450 million people annually worldwide, with over 150 million new cases in children under 5, most in developing countries. Mortality is also discussed, with over 2 million child deaths from pneumonia each year, mostly in developing nations. The document then covers etiology, risk factors like HIV, and interventions to control childhood pneumonia. It concludes by outlining Cuba's national CAP management consensus, including antimicrobial treatment guidelines based on a child's age and the severity and suspected cause of their pneumonia.
WGHA Discovery Series: David Heymann
Washington Global Health Alliance Discovery Series
David Heymann, MD
June 19, 2008
'Challenges and Controversies in Polio Eradication'
disease eradication.pptx
The document discusses disease eradication, defining it as the complete elimination of an infectious disease from the entire world. It provides criteria for determining if a disease can be eradicated, including not having an animal reservoir and having an effective intervention like a vaccine. Successful eradication programs for smallpox and rinderpest are described. Ongoing efforts targeting polio, measles and other diseases are also summarized.
MALARIA DAY - 25- APRIL- 2022.pptx
The document discusses World Malaria Day and the theme of harnessing innovation to reduce the malaria disease burden. It provides definitions and descriptions of malaria, including that it is caused by Plasmodium parasites and transmitted via infected Anopheles mosquitoes. It discusses the history of malaria, magnitude of the problem globally and in India, epidemiological determinants like parasite species, life cycle, host and environmental factors. It also summarizes diagnosis, treatment approaches, and the role of nurses in prevention and control of malaria through activities like health education, testing, and treatment adherence support.
New Value of Vaccines
1) GSK produces vaccines for diseases like pneumonia, polio, rotavirus, cervical cancer and others. Their vaccines have helped prevent up to 3 million deaths and disability in 750,000 children annually.
2) GSK's cervical cancer vaccine, Cervarix, is dedicated to preventing cervical cancer. Clinical trials showed it has nearly 100% efficacy against HPV types 16 and 18, which cause over 50% of cervical cancer cases. It also has efficacy against other high-risk HPV types and has a good safety profile.
3) GSK provides holistic support for vaccination programs including cold chain management, training, advocacy, and monitoring to help ensure vaccines are effectively delivered and utilized. They aim
Control of communicable diseases
This document summarizes several communicable diseases and control programs in the Philippines. It discusses tuberculosis (TB), focusing on the National TB Program's DOTS strategy achieving global targets. Emerging issues like drug resistance need addressing. The National Leprosy Control Program aims to ensure MDT drug availability and prevent disabilities. Schistosomiasis and its life cycle transmission via snails in contaminated water is outlined. Filariasis caused by worm transmission through mosquitoes can cause swelling and disability. The National Filariasis Elimination Program aims to eliminate it by 2017. Malaria transmitted by mosquitoes and its various causative agents are also summarized.
Malaria in Bangladesh
previous and current situation of malaria in BD, treatment, prevention, national malaria strategic plan 2915 etc.
WHO Global Technical Strategy for Malaria 2016-2030
WHO Global Technical Strategy for Malaria 2016-2030
National Framework for Malaria Elimination in India (2016–2030)
The Prick will do the Trick: Protecting our Healthcare Workers from Vaccine-P...
The Prick will do the Trick: Protecting our Healthcare Workers from Vaccine-P...Philippine Hospital Infection Control Society
Healthcare-worker Immunization Recommendation Update by Dr. Rontgene M. Solante, MD FPCP FPSMID during the 22nd Annual PHICS ConventionCurrent scenario of vbd in india
The ppt highlights types of insecticide resistance, resistance towards antimalarials, rationale of National drug policy for malaria, use of GIS in epidemic predictions for kala azar, malaria, genetically modified mosquitoes and malaria vaccine
Lymphatic Filariasis
Filariasis, a parasitic infection caused by nematodes transmitted through mosquito bites, remains a major public health problem in the Philippines. It was first discovered in the country in 1907 and prevalence rates in 1998 were estimated at 9.7% nationally. The disease primarily affects poorer areas and can lead to lymphedema, elephantiasis, and hydrocele if left untreated. The Philippines aims to eliminate filariasis as a public health problem by 2017 through mass drug administration campaigns, disability prevention programs, and surveillance of endemic areas after treatment.
Control of Communicable Diseases
This document summarizes information on tuberculosis (TB), the National Tuberculosis Program (NTP), and strategies for controlling TB in the Philippines. It states that TB is caused by the bacterium Mycobacterium tuberculosis and is transmitted through infectious droplets from coughing, sneezing, talking, or singing. The NTP achieved global targets for TB case detection and treatment success rates. However, emerging issues like drug resistance and co-morbidities need to be addressed to prevent further transmission. The program aims to reduce variations in performance, scale up coverage of DOTS implementation, and reduce out-of-pocket expenses for quality TB services.
Malaria status & challenges of the epidemic
Malaria is one of the most common infectious diseases and a great public health problem worldwide. About one million people die each year from malaria, and half of the world's population lives in areas where there is a risk of getting the disease through the bites of infected mosquitoes.
What is being done to control the spread of malaria? Can the disease be eradicated?
Similar to Carla botting malaria vaccines oct 14 2013 (20)
National Vector Borne Disease Control Program.pptx
National Vector Borne Disease Control Program.pptx
Multidrug Resistant Malaria- Vani Vannappagari MBBS PhD
Multidrug Resistant Malaria- Vani Vannappagari MBBS PhD
Multidrug Resistance malaria vani vannappagari mbbs ph d
Multidrug Resistance malaria vani vannappagari mbbs ph d
WHO Global Technical Strategy for Malaria 2016-2030
WHO Global Technical Strategy for Malaria 2016-2030
The Prick will do the Trick: Protecting our Healthcare Workers from Vaccine-P...
The Prick will do the Trick: Protecting our Healthcare Workers from Vaccine-P...
More from Rosella Anstine
Ann ginsberg
New vaccines are urgently needed that can prevent both infection and disease across all populations and strains of TB, help reduce the growing problem of drug-resistant TB, and contribute to global TB elimination efforts.
Angeline nanni
This document outlines the agenda and goals of an expert workshop on planning for adolescent and adult vaccination in middle and low income countries. The aims of the workshop are to identify current knowledge about adolescent and adult vaccination schedules, coverage rates, and barriers; determine what is known about measuring social and behavioral factors influencing adult vaccination; and identify and prioritize elements of a research agenda to inform vaccine development and effective vaccination strategies. Expected outcomes include developing a prioritized research agenda to address knowledge gaps and identifying key social and behavioral determinants of adult vaccination. The agenda covers topics on adult vaccination determinants, ethical issues, epidemiology of diseases like HIV/AIDS, TB and malaria, and implications of shifting global poverty and urbanization on disease burden and access
D.ompad
Urbanization is increasing globally, with more people living in urban areas. This presents challenges for distributing adult vaccines. The document reviews different strategies used in primary care, hospitals, targeted venues like nursing homes, large regional programs, and community-based efforts. Most focused on elderly adults, with fewer interventions for other high-risk groups or children. While various approaches were effective at increasing vaccination rates, one limitation is an inability to reach those not engaged with the healthcare system, specifically hard-to-reach urban populations.
Unicef o'connell equity and vaccine supply 5_sep13
The document discusses UNICEF's work on vaccines and equity. It notes that while progress has been made on child mortality goals, inequities remain across regions, populations, and causes of death. UNICEF aims to accelerate progress and sustain momentum post-2015 through more strategic, targeted interventions. Data insights and innovations allow identifying high-risk districts and populations. UNICEF's role in vaccine procurement for over 100 countries is described, noting increasing demand due to new vaccines. Challenges include fragile supply chains and competing priorities. Maintaining stable, affordable vaccine supply requires diversified suppliers and forecasting aligned with programs. Planning must begin early for new vaccines like typhoid to ensure equitable introduction and measurement of coverage.
Social and behavioral determinants lit review
This document provides a summary of a literature review on social and behavioral determinants of adult vaccination. The review identified 71 relevant publications, with 25 focusing on social determinants and 14 on behavioral determinants. For social determinants, key findings included barriers to adult vaccination like lack of access and programs, as well as racial/ethnic divides in vaccination rates. Models like the Diderichsen Framework and theories of intermediary determinants were also discussed. For behavioral determinants, the Health Belief Model and Theory of Planned Behavior were strong predictors of vaccination behavior based on factors like perceived benefits, barriers, and social norms. A gap identified was the lack of research on determinants in low- and middle-income countries.
Vicky cardenas
This document discusses the potential health impacts of countries graduating to middle-income country status based on a case study of tuberculosis (TB). It presents data on TB cases, prevalence, and incidence from 1990-2011 for countries that graduated to MIC status between 1999-2008, including China, Indonesia, India, Nigeria, and Pakistan. The data shows that while TB rates decreased overall for these countries after graduating to MIC status, they still face significant burdens from the disease.
David curry
This document summarizes key points from a presentation on evidence-based policy, bioethics principles, and immunization priorities for vaccine development and delivery. It discusses the importance of building consensus from evidence and analyses, considering ethical values and principles like harm, autonomy and justice, and addressing the realities of prioritization given limited resources. Bioethics can help incorporate values into policy. Ethical imperatives include accelerating vaccine access for all people regardless of location or wealth. The document seeks questions and comments on these topics.
D.ompad
Urbanization is increasing globally, with more people living in urban areas. This presents challenges for distributing adult vaccines. The document reviews different strategies used in various settings to increase adult vaccination rates. Hospital/clinic-based interventions like standing orders and reminders showed success. Community-based programs distributing vaccines in non-traditional settings also increased rates. While many focused on the elderly, few targeted high-risk adults or children. A limitation is reaching those not engaged in healthcare.
Arne naveke
This document provides an overview of HIV/AIDS, including its history, current statistics on those infected and prevalence rates in different populations. It discusses milestones in treatment and prevention efforts as well as the complexity of developing an HIV vaccine. Key challenges include the scientific difficulties of the virus integrating and rapidly mutating, as well as lack of animal models and unknown immune correlates of protection. Political and policy challenges also impact vaccine development through the need for long-term funding commitments and incentives for private sector involvement. Societal factors like ethics, culture, stigma and gender dynamics further complicate vaccine trials.
Aharona glatman freedman social determinants sept 4-5 2013 -
1) Non-biological factors like social, economic, and political determinants significantly impact the success of immunization programs. The document discusses factors in low and middle/high income countries.
2) For low income countries, key social determinants included parental education, gender inequity, rural/urban residence, accessibility of programs, and traditional healers. Governance indicators like political stability and control of corruption were better predictors of new vaccine introduction than financial healthcare indicators.
3) The introduction of new vaccines like Hib and hepatitis B in African countries from 2000-2005 showed that countries with better governance were more likely to introduce the new vaccines in the initial phase of support from GAVI.
Amanda glassman
Most of the world's poorest people now live in middle-income countries rather than low-income countries. The total disease burden has also shifted to middle-income countries, where they face a high burden from diseases like tuberculosis, measles, HIV/AIDS, and vaccine-preventable diseases. While population sizes are larger in middle-income countries, disease burdens are also high due to lagging public health prevention programs and relatively poor vaccination performance compared to their economic status. Many middle-income countries will struggle to self-finance their immunization programs based on projected costs. A new, tailored strategy is needed to address disease burdens in middle-income countries.
Aharona glatman freedman social determinants sept 4-5 2013 -
1) Non-biological factors like social, economic, and political determinants significantly impact the success of immunization programs. These include factors like parental education, access to healthcare, gender inequity, and governance.
2) When a new vaccine for tuberculosis becomes available, factors like public acceptance, financing, and sustainability will determine its adoption in immunization programs.
3) A study on factors influencing the introduction of new vaccines in African countries supported by GAVI found that better governance indicators, like political stability and control of corruption, were a stronger predictor of adoption than financial healthcare indicators. Addressing social and behavioral determinants is important for effective vaccine introduction and implementation.
More from Rosella Anstine (12)
Unicef o'connell equity and vaccine supply 5_sep13
Unicef o'connell equity and vaccine supply 5_sep13
Aharona glatman freedman social determinants sept 4-5 2013 -
Aharona glatman freedman social determinants sept 4-5 2013 -
Aharona glatman freedman social determinants sept 4-5 2013 -
Aharona glatman freedman social determinants sept 4-5 2013 -
Recently uploaded
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Patellar Instability: Diagnosis Management
Pictorial and detailed description of patellar instability with sign and symptoms and how to diagnose , what investigations you should go with and how to approach with treatment options . I have presented this slide in my 2nd year junior residency in orthopedics at LLRM medical college Meerut and got good reviews for it
After getting it read you will definitely understand the topic.
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
Unit 4: MRA 103T Regulatory affairs
This guideline is directed principally toward new Molecular Entities that are
likely to have significant use in the elderly, either because the disease intended
to be treated is characteristically a disease of aging ( e.g., Alzheimer's disease) or
because the population to be treated is known to include substantial numbers of
geriatric patients (e.g., hypertension).
SENSORY NEEDS B.SC. NURSING SEMESTER II.
Sensation is the neurological process by which we become aware of surrounding environment.
Know the difference between Endodontics and Orthodontics.
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...ayushrajshrivastava7
Regulatory Affairs
Full hand written notes
M.pharm - 1st year .Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
PGx Analysis in VarSeq: A User’s Perspective
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Do you have abnormal smell after periods? It may be vaginitis. Do not worry, herbal medicine Fuyan Pill can help you get a cure.
Nano-gold for Cancer Therapy chemistry investigatory project
chemistry investigatory project
The development of nanogold-based cancer therapy could revolutionize oncology by providing a more targeted, less invasive treatment option. This project contributes to the growing body of research aimed at harnessing nanotechnology for medical applications, paving the way for future clinical trials and potential commercial applications.
Cancer remains one of the leading causes of death worldwide, prompting the need for innovative treatment methods. Nanotechnology offers promising new approaches, including the use of gold nanoparticles (nanogold) for targeted cancer therapy. Nanogold particles possess unique physical and chemical properties that make them suitable for drug delivery, imaging, and photothermal therapy.
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS). Parc Taulí. Sabadell
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
cosmetics and cosmeceuticals
Muskan
mpharm
2nd semester
Guru Gobind Singh college of pharmacy, yamunanagar, haryana
What are the different types of Dental implants.
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
Recently uploaded (20)
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Pune Call Girls 7339748667 AVAILABLE HOT GIRLS AUNTY BOOK NOW
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Tele Optometry (kunj'sppt) / Basics of tele optometry.
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
STUDIES IN SUPPORT OF SPECIAL POPULATIONS: GERIATRICS E7
Know the difference between Endodontics and Orthodontics.
Know the difference between Endodontics and Orthodontics.
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Full Handwritten notes of RA by Ayush Kumar M pharm - Al ameen college of pha...
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Post-Menstrual Smell- When to Suspect Vaginitis.pptx
Nano-gold for Cancer Therapy chemistry investigatory project
Nano-gold for Cancer Therapy chemistry investigatory project
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
acne vulgaris -Mpharm (2nd semester) Cosmetics and cosmeceuticals
Carla botting malaria vaccines oct 14 2013
- 1. PLANNING FOR ADULT VACCINATION WORKSHOP AERAS - SEPT 4, 5, 2013 Malaria Vaccines Change from control to elimination/ eradication Carla Botting Director Product Development and Access
- 2. Malaria Disease Burden Malaria epidemiology: • Globally, 3.3 billion at risk of malaria* • ~219 million (154M-289M) cases/year, 79% in sub-Saharan Africa • 90% of these cases are caused by P. falciparum • ~660,000 (490K-896K) deaths/year, 90% in sub-Saharan Africa * WHO World Malaria Report 2012 Pf EIR >100 10 1 0.1 Gething, P.W., et al., A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J, 2011. 10: p. 378. 2
- 3. 2006 Malaria vaccine community goal Strategic Goal * : To develop an 80% efficacious malaria vaccine by 2025 that would provide protection for at least four years – Landmark Goal: To develop and license a first-generation malaria vaccine that has protective efficacy of more than 50% against severe disease and death and lasts longer than one year Malaria Vaccine Technology Roadmap http://www.malariavaccineroadmap.net/ *WHO is currently leading the process to revise to the Strategic Goal – the Landmark Goal will not change 3
- 4. Updated Strategic Goal & Outcomes • A world free of malaria in part due to affordable access to malaria vaccines that prevent disease and death caused by and/or interrupt transmission of P. falciparum and P. vivax in all ages and in all endemic settings. Goal/Impact Outcome Transmission Interrupted Saving Lives & Preventing Disease Control & Elimination Infections Prevented Cases Averted* *Impact on asymptomatic reservoir? 4 4
- 5. Updated Strategic Goal, Outcomes, & Targets • A world free of malaria in part due to affordable access to malaria vaccines that prevent disease and death caused by and/or interrupt transmission of P. falciparum and P. vivax in all ages and in all endemic settings. Saving Lives & Preventing Disease Goal/Impact Control & Elimination Outcome Transmission Interrupted Infections Prevented Cases Averted* Sexual/ Sporogonic/ Mosquito (SSM) Preerythrocytic (PE) Blood Stage (BS) Vaccine Target 5 5
- 6. Three priority program areas • A world free of malaria in part due to affordable access to malaria vaccines that prevent disease and death caused by and/or interrupt transmission of P. falciparum and P. vivax in all ages and in all endemic settings. Goal/Impact Outcome Transmission Interrupted Saving Lives & Preventing Disease Control & Elimination Infections Prevented Cases Averted* Vaccine Target 4 priority program areas TBVs ppRTS,S & eeRTS,S Next Gen 6 6
- 7. RTS,S present and future ppRTS,S Prevention of pediatric malaria RTS,S eeRTS,S Elimination / eradication RTS,S Current TPP for RTS,S, which focuses on prevention of pediatric malaria clinical and severe disease Evaluation of current RTS,S construct to determine whether it could facilitate elimination in some settings Would require deploying the current construct to the entire population at risk, not just infants / toddlers eeRTS,S+ Next generation elimination / eradication RTS,S Adding components to the current RTS,S construct to make a more highly efficacious malaria vaccine that could contribute to elimination in an entire at risk population 7
- 8. THANK YOU